Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| PHRC/00-01 | Other Identifier | Rennes University Hospital | |
| CIC0203/004 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ministry of Health, France | OTHER_GOV |
| Yamanouchi | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Ureteral stones have an important place in daily urological practice, usually causing acute episodes of ureteral colic by obstructing the urinary tract. The aim of the study is to evaluate whether repeated administration of tamsulosin, a drug routinely used in the treatment of lower urinary tract symptoms, could lower the delay of elimination of the stone in patients with pelvis ureterolithiasis.
Ureteral colic, mainly due to ureterolithiasis, represents 1 to 2% of hospital emergency admissions. When a surgical intervention is not required, usual treatment combines hydration and anti-inflammatory drugs.
Alpha1-blockers, firstly developed as anti-hypertensive drugs, are now also used in the management of benign prostatic hyperplasia, due to their relaxing properties on the urinary tract. The aim of the study is to investigate whether tamsulosin could lower the delay of elimination of the stone in patients with pelvis ureterolithiasis. Patients are randomized to receive either tamsulosin or a placebo in addition to usual treatment until stone elimination. Efficacy is assessed by evaluating the time to spontaneous passage of the stone between day 1 and day 42, the need for surgery and pain recurrences.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Tamsulosin |
|
| 2 | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tamsulosin | Drug | Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time to stone elimination in days (censored criterion) | between day 1 and 42 |
| Measure | Description | Time Frame |
|---|---|---|
| Time to stone elimination in days in patients with spontaneous elimination (quantitative criterion) | between day 1 and 42 | |
| Pain using Visual Analogue Scale | days 1, 2, 3 | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Francois Guillé, MD | Rennes University Hospital | Principal Investigator |
| Eric Bellissant, MD, PhD | Rennes University Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Service d'Urologie- Hôpital du Val de Grâce | Paris | 75005 | France | |||
| Service d'Urologie - Hôpital de La Milétrie |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 16045553 | Background | Resim S, Ekerbicer H, Ciftci A. Effect of tamsulosin on the number and intensity of ureteral colic in patients with lower ureteral calculus. Int J Urol. 2005 Jul;12(7):615-20. doi: 10.1111/j.1442-2042.2005.01116.x. | |
| 8957159 | Background | Wilde MI, McTavish D. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs. 1996 Dec;52(6):883-98. doi: 10.2165/00003495-199652060-00012. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D053039 | Ureterolithiasis |
| D014514 | Ureteral Calculi |
| ID | Term |
|---|---|
| D014515 | Ureteral Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077409 | Tamsulosin |
| ID | Term |
|---|---|
| D000096926 | Benzenesulfonamides |
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days) |
|
| Spontaneous stone elimination rate |
| days 1, 7, 14, 21, 28, 35, and 42 |
| Spontaneous stone elimination rate, according to stone size (2-3 mm, 4-5 mm, 6-7 mm) | days 1, 7, 14, 21, 28, 35, and 42 |
| Rate of need for surgery | Within 42 days |
| Time to surgery in days in patients with surgical elimination | between day 1 and day 42 |
| Rate of pain recurrences | within 42 days |
| Time to the first recurrence in days | between day 1 and day 42 |
| Rate of need for corticoids or morphine | Within 42 days |
| Time to the first administration of corticoids or morphine in days | between day 1 and day 42 |
| Rate of adverse events | Within 42 days |
| Poitiers |
| 86021 |
| France |
| Hôpital de Redon | Redon | 35600 | France |
| Service d'Urologie- Hôpital Robert Debré | Reims | 51092 | France |
| Service d'Urologie- Hôpital Pontchaillou | Rennes | 35033 | France |
| Service d'Urologie - Hôpital Bretonneau | Tours | 37044 | France |
| 21149761 | Derived | Vincendeau S, Bellissant E, Houlgatte A, Dore B, Bruyere F, Renault A, Mouchel C, Bensalah K, Guille F; Tamsulosin Study Group. Tamsulosin hydrochloride vs placebo for management of distal ureteral stones: a multicentric, randomized, double-blind trial. Arch Intern Med. 2010 Dec 13;170(22):2021-7. doi: 10.1001/archinternmed.2010.447. |
| D000091642 | Urogenital Diseases |
| D052878 | Urolithiasis |
| D052801 | Male Urogenital Diseases |
| D014545 | Urinary Calculi |
| D002137 | Calculi |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001555 |
| Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |